• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国普通人群和特应性皮炎患者中癌症的发病率

Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K.

机构信息

Risk Management Resources, Pharmacovigilance Services SL, 50001 Zaragoza, Spain.

出版信息

Br J Dermatol. 2010 Nov;163(5):1036-43. doi: 10.1111/j.1365-2133.2010.09887.x.

DOI:10.1111/j.1365-2133.2010.09887.x
PMID:20545690
Abstract

BACKGROUND

Atopic dermatitis (AD) affects approximately 20% of children and 1-3% of adults in developed countries.

OBJECTIVE

To study the incidence of cancer in patients with AD in the U.K. general population.

METHODS

We conducted a follow-up study in the U.K. using The Health Improvement Network (THIN) database. We calculated the incidence rate (IR) of the first occurrence of overall cancer, lymphoma, melanoma and nonmelanoma skin cancer (NMSC) in the general population, in patients with AD and in individuals without AD. In addition we calculated the IR ratio (IRR) of overall cancer and subtypes of cancer in patients with AD vs. those without.

RESULTS

The study population included 4,518,131 patients [2,336,230 (51·7%) female]. There were 129,972 subjects [68,688 (52·8%) female] with a diagnosis of cancer (excluding NMSC). The IR (per 10,000 person-years) of cancer (excluding NMSC) was 42·41 [95% confidence interval (CI) 42·18-42·64]; of lymphoma 1·70 (95% CI 1·65-1·74); of skin melanoma 1·71 (95% CI 1·67-1·76) and of NMSC 11·76 (95% CI 11·64-11·88). The age- and sex-adjusted IRR for cancer (excluding NMSC) was 1·49 (95% CI 1·39-1·61); for lymphoma 2·21 (95% CI 1·65-2·98); for melanoma 1·74 (95% CI 1·25-2·41); and for NMSC 1·46 (95% CI 1·27-1·69).

CONCLUSIONS

Our results indicate an increased incidence of cancer overall as well as of specific cancer subtypes, including lymphoma, in patients with AD. Further studies are needed to disentangle the effects of treatment for AD from AD itself.

摘要

背景

特应性皮炎(AD)影响大约 20%的儿童和发达国家 1-3%的成年人。

目的

研究英国普通人群中 AD 患者的癌症发病率。

方法

我们在英国使用健康改善网络(THIN)数据库进行了一项随访研究。我们计算了普通人群、AD 患者和无 AD 个体中总体癌症、淋巴瘤、黑色素瘤和非黑色素瘤皮肤癌(NMSC)首次发生的发病率(IR)。此外,我们还计算了 AD 患者与无 AD 患者的总体癌症和癌症亚型的发病率比(IRR)。

结果

研究人群包括 4518131 名患者[2336230 名(51.7%)为女性]。有 129972 名患者[68688 名(52.8%)为女性]被诊断患有癌症(不包括 NMSC)。癌症(不包括 NMSC)的发病率(每 10000 人年)为 42.41[95%置信区间(CI)42.18-42.64];淋巴瘤为 1.70[95%CI 1.65-1.74];皮肤黑色素瘤为 1.71[95%CI 1.67-1.76];NMSC 为 11.76[95%CI 11.64-11.88]。癌症(不包括 NMSC)的年龄和性别调整发病率比(IRR)为 1.49[95%CI 1.39-1.61];淋巴瘤为 2.21[95%CI 1.65-2.98];黑色素瘤为 1.74[95%CI 1.25-2.41];NMSC 为 1.46[95%CI 1.27-1.69]。

结论

我们的结果表明,AD 患者的总体癌症发病率以及特定癌症亚型(包括淋巴瘤)均升高。需要进一步研究来阐明 AD 治疗与 AD 本身的影响。

相似文献

1
Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K.英国普通人群和特应性皮炎患者中癌症的发病率
Br J Dermatol. 2010 Nov;163(5):1036-43. doi: 10.1111/j.1365-2133.2010.09887.x.
2
Malignancy risk in patients with atopic dermatitis: a population-based cohort study.特应性皮炎患者的恶性肿瘤风险:一项基于人群的队列研究。
Br J Dermatol. 2023 Jul 7;189(1):53-61. doi: 10.1093/bjd/ljad072.
3
Incidence of cancer among patients with atopic dermatitis.特应性皮炎患者的癌症发病率。
Arch Dermatol. 2005 Sep;141(9):1123-7. doi: 10.1001/archderm.141.9.1123.
4
Incidence of Cardiovascular Disease and Venous Thromboembolism in Patients With Atopic Dermatitis.特应性皮炎患者心血管疾病和静脉血栓栓塞的发生率。
J Allergy Clin Immunol Pract. 2023 Oct;11(10):3123-3132.e3. doi: 10.1016/j.jaip.2023.08.007. Epub 2023 Aug 10.
5
The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study.台湾地区银屑病患者罹患非黑素瘤皮肤癌、淋巴瘤和黑素瘤的风险:一项基于人群的 10 年队列研究。
Int J Dermatol. 2012 Dec;51(12):1454-60. doi: 10.1111/j.1365-4632.2011.05310.x.
6
Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway.在挪威全国处方登记研究中婴儿和幼儿特应性皮炎的发病趋势。
JAMA Netw Open. 2018 Nov 2;1(7):e184145. doi: 10.1001/jamanetworkopen.2018.4145.
7
Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977-2006).特应性皮炎与皮肤癌风险:丹麦全国队列研究(1977-2006 年)。
Am J Clin Dermatol. 2012 Feb 1;13(1):29-36. doi: 10.2165/11593280-000000000-00000.
8
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
9
Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.英国特应性皮炎患者和/或接受局部免疫抑制剂治疗的患者中的淋巴瘤
J Allergy Clin Immunol. 2009 May;123(5):1111-6, 116.e1-13. doi: 10.1016/j.jaci.2009.02.028. Epub 2009 Apr 10.
10
Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.外用他克莫司治疗特应性皮炎患者的非黑色素瘤皮肤癌
J Dermatolog Treat. 2005 Aug;16(3):149-53. doi: 10.1080/09546630510041088.

引用本文的文献

1
Skin cancer prevention in the Polish population during the COVID-19 pandemic.新冠疫情期间波兰人群的皮肤癌预防
Front Public Health. 2025 Jun 20;13:1452043. doi: 10.3389/fpubh.2025.1452043. eCollection 2025.
2
The association between allergy and risk of brain tumors: Evidence from 40 observational studies.过敏与脑肿瘤风险之间的关联:来自40项观察性研究的证据。
Acta Neurochir (Wien). 2025 Apr 21;167(1):111. doi: 10.1007/s00701-025-06499-3.
3
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel.
特应性皮炎的风险评估:多学科专家小组的指导意见
Dermatol Ther (Heidelb). 2025 May;15(5):1063-1078. doi: 10.1007/s13555-025-01391-5. Epub 2025 Mar 31.
4
The Association between Allergy and Cancer: A Case-Control Study.过敏与癌症的关联:病例对照研究。
Asian Pac J Cancer Prev. 2024 Aug 1;25(8):2787-2795. doi: 10.31557/APJCP.2024.25.8.2787.
5
Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis.特应性皮炎中生物疗法和选择性Janus激酶-1抑制剂引发恶性肿瘤风险的系统评价和网状荟萃分析
Postepy Dermatol Alergol. 2024 Jun;41(3):270-275. doi: 10.5114/ada.2024.141125. Epub 2024 Jun 30.
6
The causal effect of atopic dermatitis on lung cancer: A Mendelian randomization study.特应性皮炎对肺癌的因果关系:一项孟德尔随机化研究。
Skin Res Technol. 2024 Jul;30(7):e13841. doi: 10.1111/srt.13841.
7
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.阿泊替尼治疗中重度特应性皮炎 3802 例患者的综合安全性更新:5200 多患者年数据,最长达 4 年暴露。
Am J Clin Dermatol. 2024 Jul;25(4):639-654. doi: 10.1007/s40257-024-00869-w. Epub 2024 Jun 18.
8
Association between Atopic Dermatitis and Colorectal Cancer: TET2 as a Shared Gene Signature and Prognostic Biomarker.特应性皮炎与结直肠癌之间的关联:TET2作为共同的基因特征和预后生物标志物
J Cancer. 2024 Jan 20;15(5):1414-1428. doi: 10.7150/jca.92238. eCollection 2024.
9
Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis.中重度特应性皮炎患者发生肾恶性肿瘤的风险增加。
Cancers (Basel). 2023 Oct 16;15(20):5007. doi: 10.3390/cancers15205007.
10
Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study.局部使用钙调磷酸酶抑制剂与特应性皮炎患者癌症风险的相关性:一项全国性、基于人群的回顾性队列研究。
Am J Clin Dermatol. 2023 Sep;24(5):799-808. doi: 10.1007/s40257-023-00787-3. Epub 2023 Jun 6.